The O
virological O
clearance O
rate O
of O
throat O
swabs, O
sputum, O
or O
lower O

Length O
of O

Compliance O

nan O

Symptomatic O
non-COVID O
viral O
infection O

nan B-outcome

Positive I-outcome
SARS-CoV-2 I-outcome
rt-PCR O
test O

Number O
of O
asymptomatic O
cases O

28-day O
mortality O
Duration O
of O
mechanical O

Acute O
respiratory O
illness O
Absenteeism O
Lower O

28-day O
mortality O
Duration O
of O
mechanical O
ventilation O

Geometric O
mean O
fold O
rise O
(GMFR) O
in O
IgG O

Safety O
indexes O
of O
adverse O

nan O

Traditional O
Chinese O

body O
temperature O

Hepatorenal O
function O
Heart O
rate O
Blood O

nan O

nan O

Vital O
signs O

Clinical O
manifestations O
and O
severity O
of O

nan O

self-assessment O
scale O
moxa O
related O
Questionaire O
NCP O
related O

New O
coronavirus O
infection O
before O

Incidence O
of O
fever O
Incidence O
of O
cough O
Incidence O

nan O

nan O

nan O

nan O

nan O

adverse O
reactions O
28 B-outcome
days I-outcome
post I-outcome
injection I-outcome
SAE I-outcome
anti-S I-outcome

Time-to-first O
clinical O
event O

nan O

SARS-CoV-2 B-outcome
seroconversion I-outcome
Occurrence O

Rate O
of O
participant-reported O
adverse O
events O
Incidence O
rates O
of O

nan O

Adverse O
events O
Adverse B-outcome
events I-outcome

Evaluation I-outcome
of I-outcome

COVID-19 O
incidence O
by O
12 O
months B-outcome
Severe I-outcome
COVID-19 O

Assess O
the O
safety, B-outcome
tolerability I-outcome
and I-outcome
reactogenicity B-outcome
profile I-outcome
of I-outcome

The O
cumulative O
incidence O
of O
documented B-outcome
SARS-CoV-2 I-outcome
infection O

COVID-19 O
disease O
symptoms B-outcome
severity I-outcome
Adverse I-outcome
effects I-outcome

nan I-outcome

Number I-outcome

Adverse O
events O
Symptomatic B-outcome
COVID-19 I-outcome
disease I-outcome
Seropositivity I-outcome
Days I-outcome
of I-outcome

Number O
of O
Covid-19 O
positive B-outcome
participants I-outcome

Incidence O
of O
confirmed O
SARS-CoV-2 O
detection O
Incidence O
of O
possible O
COVID-19 O

Mean O
oxygen O
flow B-outcome
Time O

Positive O
serology O
at O
day O
28 O
Symptoms O
of O
COVID-19 O

nan O

Severity O
of O
disease O
in O
confirmed O

nan O

Antibody-screening O

nan O

SARS-CoV-2 O
Antibodies O
Incidence O
of O
COVID-19 O
infection O
bacTRL-Spike O
in O
stool O
post-vaccination O
Seroconversion O
of O
circulating O
anti-Spike O
IgG O
antibodies O
& O
stability O
of O

Prevention O
Study: O
Measure O
the O
effect O
of O
NORS O
on O
the O
prevention O
of O
progression O
of O
COVID- O
19 O
Prevention O
Study: O
Measure O
the O
tolerability O
of O
NORS O

Severity O
of O
Disease O

absence O

Reducing O
clinical O
episodes O
due O
to O

Effect O
of O
basic O

Viral O

Comparison O

Occurrence O

nan O

Salivary O
cytokine O

nan O

COVID19-related O
disease O

Percent O
of B-outcome
agreement I-outcome

ICU O
transfer B-outcome
Oxygen O

nan O

Rapid O
Assessment O
of O
Physical O
Activity O
Global O
Rating O
of O
Change O

o O
28-day O
mortality O
o O
Need O
for O
ICU O

Incidence O
of O
symptomatic O
SARS-CoV-2 O
infections O
Symptom O
severity O
of O
COVID-19 O
Duration O
of O

COVID-19 B-outcome
symptom I-outcome
score, I-outcome
Integral I-outcome

Effectiveness O
of O
the O
different O
media O
outlets O

Adverse O
event O
reported O
Diagnosis O
of O
SARS-CoV-2 O
COVID-19 O
infection O

Mortality, O
gravity O
of O
COVID-19 O

1) O

Number O

nan O

nan O

Number O

Interleukin-6 O
level O
Lymphocyte O
count O
CRP O
(C-reactive O
protein) O
level B-outcome
PaO2 I-outcome
(partial I-outcome
pressure O
of O
oxygen) O
/ O
FiO2 O

nan O

nan O

nan B-outcome

nan O

nan O

nan O

nan O

nan I-outcome

nan I-outcome

Conversion O
rate O
of O

nan O

nan O

nan O

nan B-outcome

nan I-outcome

nan O

nan O

nan O

nan O

nan O

Length O
of O

nan O

nan O

nan B-outcome

nan I-outcome

Rate O
of O

nan O

nan O

nan O

nan O

nan O

nan O

Time O
to I-outcome
improvement I-outcome
in O
oxygenation O

Change O
in O
National O
Early O
Warning O
Score O

RT-PCR O
results O

All O
cause O
mortality O

Percentage O

Change O

body O

Viral O

Mortality O

Number O
of O
patient O

Not O
provided O

Rate O

PaO2 O

28-Day O

Examine O
the O
percentage O
of O

Clinical B-outcome
status I-outcome
assessed O
according O
to O
the O

Proportion O
of O
Participants O
With O
Treatment O

Time O
to O

Proportion O
of O
Participants O
With O
Treatment O
Emergent O
Adverse O
Events O

TNF O
alpha O
Multi-system O
organ O
failure O

Proportion O
of O
patients O
in O
each O
classification O
of O

nan O

The O
degree O
of O
remission O
of O
symptoms O

nan O

All O
cause O
mortality O

Clinical O
status O
Time O
to O
Hospital O
Discharge O
OR O
NEWS2 O
(National O

Time O
to O
CoVID-19 O
RT-PCR O
negative O
in O
upper O

Clinical B-outcome
remission O
rate O
Dynamic O
changes O
of O
oxygenation O
index O
Time O

absolute O
lymphocyte I-outcome
counts I-outcome
serum O
level I-outcome
of O
CRP, O
PCT O
and O
IL-6 O
SOFA O
score O
all O

clinical O
cure O
incidence O
in O
14 O
days O
the O
duration O
of O
virus O
change O
to O

28 O
day O
mortality O

Clinical O
status O
assessed O
by O

Times O
of O
acute O
exacerbation O
Six-minute O
walk O
distance O
Dyspnea O
Scores O
Composite O
physiological O
index O

Degree O
of O
dyspnea O
(Liker O
scale) O

28-day O
mortality O
Duration O
of O
mechanical O
ventilation O
Duration O
of O
hospitalization O
Proportion O
of O
patients B-outcome
with I-outcome
negative I-outcome
RT-PCR I-outcome

Improvement O
of O
Clinical O
symptoms O

Time O
to O
recovery O

All O
cause O
mortality O
Frequency O
of O
respiratory O
progression O

The O
incidence O

Rate O
of O
normal O
tempreture O

Time O
of O
clinical O
remission O
Rate O
of O
no O
fever O
Rate B-outcome
of O
no O
cough O
Rate O
of B-outcome
no O
dyspnea O
Rate O
of O

Rate O
of O

Rate O
of O
no O
fever O

Incidence O
of O
Hospitalization O

Change O
from O
baseline O
in O
alanine O
transaminase O
(ALT) O
Change O
from O
baseline O
in O
aspartate O

Virus O
negative O
conversion O
rate O
Antipyretic O
rate O
Symptom O
relief O
time O
Finger O

28-days O
mortality O
ICU O
length O
of O
stay O
Demand O
for O

nan O

Clinical O
status O
Time O
to O
Hospital O
Discharge O
OR O
NEWS2 O

Number O
of O
participants O
with O
treatment-related B-outcome
adverse I-outcome
events O

The O
virological O
clearance O
rate O
of O
throat O
swabs, B-outcome
sputum, O

Side O
effects O
in O
the O
UC-MSCs O

need O
of O
oro-tracheal O

Time O
of O
virus O

Time O
to O
recovery B-outcome
Rate I-outcome

Complete O
fever O
time O
Cough O
relief O
time O
Virus O
negative O
time O
Incidence O
of O
severe O
or I-outcome
critical O
neocoronavirus O
pneumonia O

The O
difference O
of O
PaO2/FiO2 O
between O
two O
groups O

Viral O
nucleic O
acid O
test O
negative O
conversion O
rate O
and O
days O
from O
positive O
to O
negative O
Duration O
of O

Absorption O

Time O
from O
patient B-outcome
enrollment O
to O

Time O
to O
negative O
saliva O
Time O

death O
Time O
to O
disease O
progression O
or O
death O
within O
4 O
weeks O
blood O
viral O
nucleic B-outcome
acid I-outcome
dyspnea O
score O
blood O
cough O
scores O

the O
incidence O
of O
hypoxia, O

mortality O
laboratory O

clinical O
status, O

Secondary O
indicator( O
Length O
from O
the O
day O
of O
admission O
to O
the B-outcome
day I-outcome
returning O
to B-outcome
normal I-outcome
body I-outcome

Secondary O
indicator B-outcome
(Total O
duration O
of O
disease O
Time O
needed O
for O
healing O
Incidence O
of O
adverse O
events O
Number O
of O
sequelae O
SF-36 O
Mental O
health O
scale O
) O

Secondary O

Secondary O
indicator O
( O
ICU O
stay O
duration O
Viral O
titers O

ADR O

Secondary O
indicator O
(Effective B-outcome
rate O
of O
TCM O
symptoms O
antipyretic O
time O
clearance O
time O

Secondary O
indicator O
(Chest O
imaging O
6-minute O
walking O
distance O
Pulmonary O
function O
EQ-5D O

Secondary O
indicator O
(vital B-outcome
signs I-outcome

Secondary O
indicator O
( O
Virus O
negative O

Secondary B-outcome
indicator( I-outcome
Safty O
Blood O
biochemistry O

Others O
(liver O
and O
kidney O
function, O
muscle O
enzymes, O
myoglobin) O

Clearance O
rate O
and O
time O
of O
main O
symptoms O
(fever, O
fatigue, O
cough) O
immune O
indices O

nan O

Pneumonia O
symptoms O
oxygenation O
index O
Routine O

Total O
duration O
of O

Length O
from O
the O
day O
of O
admission O
to O
the O
day O
returning O
to O
normal O
body O
temperature, O
from O
admission O
to O
two O

Time O
of O
virus O
turning O
negative O
Severe O
conversion O
rate O
Inflammation O

Clinical O
symptoms O
(fever, O
weakness, O
gastrointestinal O
discomfort, O
etc.) O
remission O
and O

nan O

Tempreture O
PSI O
score O

Improvement O
of O
TCM O
syndromes B-outcome
Relief I-outcome
of O
clinical O
symptoms O
(fever, O
fatigue, O
gastrointestinal O

Progression O
rate O
of O
2019-nCoV O
pneumonia O
Rate O
of O
severe O

nan O

time O
to O
temperature O
normal O
breath O
symptoms O
and O
measure O
hospitalization O
days O

CT O
X-ray O
Arterial O

nan B-outcome

6-minute I-outcome
walk I-outcome
test, O
6MWT O

Arterial O
Oxygen O
Saturation O
Critical O

nan O

nan O

Time O
from O
admission O
to O
clinical B-outcome
remission: I-outcome
Improvement I-outcome

Conversion O
rate O
of O
common O
and O
critical O
illness O
Nucleic O

nan O

Routine O
blood O
test O
Biochemical B-outcome
Indicators I-outcome
Blood O
gas O
analysis O
C-reactive O

nan O

nan O

Antipyretic O
time O
Pulmonary B-outcome
function I-outcome
mortality I-outcome
and O

Hospitalization O
day O
Ventilator O
utilization O
mortality B-outcome

Rate I-outcome
of I-outcome
disisolation B-outcome
TCM I-outcome
symptom I-outcome

nan O

28-day O
prognosis O
84-day B-outcome
prognosis I-outcome
Chest I-outcome
imaging O
SF-36 O

Hemodiafiltration O
Mechanical O
ventilation O
time B-outcome
Application B-outcome
of Seperator
pulmonary I-outcome
surfactant I-outcome
Oxygen O
time B-outcome
(hours) Seperator
ICU I-outcome

Time O
to O
improvement B-outcome
of I-outcome
Virus O
infection O
symptoms O
Length O
of O

pulmonary O
CT O
chest O

Body O
temperature O
3CL O
Mpro O
of O
Coronavirus O
Routine O

nan O

The O
time O
from O
the O

Liver O
function O

nan O

CRP O
HRV O

Virus O
negative O
conversion O
rate O
Symptom O
relief O
time O
Antipyretic O
rate O
Finger O
oxygen O
improvement O
rate O
Disease O
progression O
rate O
Mortality O
rate O
Change O
curve O
of O
peripheral O
blood O
lymphocyte O
count O
Incidence O
of O
severe O
adverse O
reactions O

nan O

nan O

nan O

CT O
X-ray O
Arterial O
blood O
gas O
analysis O
Assisted O
breathing O
use O
time O
mortality O
Disease O
evolution O
hospitalization O
day O
Safety O
outcome O
index O

incidence O
of O
mechanical O
ventilation O
by O
day14 O
Incidence O

all O

Length O
of O
stay O

Viral O
nucleic O
acid O
turns O

28-day O
all-cause O
mortality O
total O
length O
of O
hospitalization O
ICU O
admission O

Improvement O
rate B-outcome
in O

28-day O

Time O

Time O

Clinical O

the O

nan O

nan O

Incidence O

Disappearance O

6-minute O
walk O
test, O
6MWT O

nan O

Modified O

Pulmonary O

nan O

nan O

nan O

Arterial O

Conversion O

28-day O

nan O

Major O

nan O

Main O
clinical O

1.The O

novel O

nan O

Rate O

nan B-outcome

PHQ-9 I-outcome
Length O
of O
hospital O
stay O
Respiratory O
symptoms O

nan O

Self-rating O

Conversion O

Antifebrile O

Antifebrile O

All-cause O

nan B-outcome

nan I-outcome

blood I-outcome
pressure O
heart I-outcome
rate O
immunoglobin O
level O

cure O
rate O
All-cause O
mortality O
Severity O
rate O

nan O

Day O
7, O
14, O
21, O
28 O
clinical O
status O
Time O
from O
study O
entry O
to O

Time O
to O
2019-nCoV O
RT-PCR O
negativity O
in O
upper O

CRP O
IL-6 O

Trough O
and O

Improvement O
of O

COVID-19 O
RNA O
negative O

nan O

mortality O
Ventilator O
utilization O
Hospitalization O
day O

Frequency O
of O
exacerbations O
of O
dyspnea O
Antipyretic O

All O
cause O

nan O

nan O

Clearance O
rate O

1. O
28-day O
clinical O
improvement O
time: O
the O
number O
of O
days O
from O
randomization B-outcome
to O
clinical B-outcome
improvement.Clinical O

nan O

Physical O
activity O

Sputum O
suction B-outcome
amount O
Circulation O
indicators: O
blood O
pressure, I-outcome

Survival O
rate O

nan B-outcome

Within I-outcome

The O
7-point O
scale O
The O
rate O
of O

TTCR, O
Time O
to O
Clinical O
Recovery O
Pulmonary O

routine O
blood O
test O
blood O
biochemical O
routine B-outcome
urine I-outcome
test B-outcome
Sepsis O

nan O

nan O

nan O

Chest O
imaging O
Refers O
to O
oxygen O

Nucleic O
acid O
detection O
of O
pharyngeal O
test O
Leukocytes O
and O
lymphocytes O
in O
blood O
routine O

7 O

novel O
coronavirus O

Routine O
blood O
test O
C-reactive O
protein O

nan O

nan B-outcome

6-minute O
walk B-outcome
test I-outcome
basic O
ADL O
IADL O

Antipyretic O
time O
Pulmonary B-outcome
CT I-outcome
inflammatory O
absorption O
Time O
of O
nucleic O

30-day O
all-cause O
mortality O
Normal O
time O
of O
respiratory O

Time O

including O
AE, O

nan O

Conversion O
rate O
of O
severe O
type O
to O
general O
type O
Conversion O
rate O
of O

Time O
for O
body O
temperature O
to O

Time O
to I-outcome
defervescence I-outcome
Time O
to O
absence O

fever O
feeble O
novel O
coronavirus O
nucleic O
acid O
detection O
Lung O
CT O

rate O
of O
composite O
advers O
outcomes O

Duration O
of B-outcome
hospitalization I-outcome
proportion I-outcome
of I-outcome
mechanical I-outcome
ventilation O
use O
mortality O

nan O

Safety O
observation O
index O

all-cause O
mortality O
of O
28-days O
Transition O
time O
of O

Proportion O
of O
subjects O
with B-outcome
6-grades O
rating O
form O
at O

mortality B-outcome
on I-outcome
day I-outcome
28 I-outcome
The O
rate I-outcome
of I-outcome
negative O

All-cause B-outcome
death I-outcome
Adverse I-outcome
events O

Time O

Mechanical O
ventilation B-outcome
time I-outcome
(days) I-outcome
Total O

ICU B-outcome
stay I-outcome
period I-outcome
Incubation I-outcome
period O
IL-6 O

TTCR, O
Time O
to O

nan O

Laboratory O
examination O

Clinical O
remission O
rate O
and B-outcome
time I-outcome
novel O
coronavirus O
nucleic O

Time B-outcome
to O

Time B-outcome
for I-outcome
improvement I-outcome
of O
clinical O

Treatment O
compliance O
To O
evaluate O
the O

NEW O
Score O
Hospital O
Stay O
30-day O
all-cause O
mortality O
Levels O
of O
Inflammatory O
Factors O
and O
Oxidative O

body O
tempture O
lung O
CT O
scan O
clearance O
time O
of O
COVID-19 O
Oxygen O
saturation O
duration O

nan O

nan O

the O
incidence O
of O
hypoxia O
the O
times O
of O
intubation O
7-day O
mortality O

SF-36 O
score O

nan O

Clinical O
improvement O
scores O
at O
Day O
28 O
Mechanical O
ventilation O
time O

The O
fading O
and O
obviously O
improving O
time O
of O

Comparison O
of O
TCM O
symptom O
score O

Clinical O
improvement O
scores O
at O
Day O

Time O
to O
COVID-19 O
RNA O
convert O
negative O
Other O
symptoms O
relief O

nan B-outcome

nan I-outcome

Immunological O
indexs O
Procalcitonin O
Coagulation O
routine O

nan O

Single O
symptom O
disappearance B-outcome
rate I-outcome

Time B-outcome
and I-outcome
rate I-outcome
of I-outcome
coronavirus O
become I-outcome
negative I-outcome
Proportion O

28-day B-outcome
mortality I-outcome
Hospitalization I-outcome
time I-outcome
ICU O
hospitalization O
Invasive O
mechanical O

nan O

Viral O
nucleic B-outcome
acid I-outcome

nan O

nan O

pH O
Oxygenation O
index O
PaCO2 O

nan O

Clinical O

nan O

Pneumonia O
symptoms O
oxygenation B-outcome
index I-outcome

nan O

C-reactive O
protein B-outcome
Detection I-outcome

Hospital O
stay O
Inflammatory O
factor O

Haematological O
C-reactive O
protein B-outcome
Blood I-outcome

28 O
natural O
survival O
rate O

nan O

nan O

SOFA O
score, O
APACHE O
II O
score O
time O
of O
mechanical O
ventilation O
Complications O

traditional O
Chinese O
medical O
syndrome O
scale B-outcome
TCM I-outcome
symptom O
integral O
TCM O
Constitution O
body O
temperature O
Serum O
antibody O
cellular O
immune O
factor O

Total B-outcome
hospital I-outcome
stay I-outcome

All B-outcome
cause I-outcome
mortality I-outcome
Frequency O
of O
exacerbation O
of O
dyspnea O

28-day O
mortality O

nan O

Lung O
function O

The B-outcome
incidence I-outcome
of I-outcome
mild I-outcome
or O
common O
novel O
coronavirus O
pneumonia O

The O
incidence B-outcome
of I-outcome
mild O
or O
common O
novel O
coronavirus O
pneumonia O
progressing O
to O
severe O
Time O
for O
the O
main O

Clearance O
rate B-outcome
and I-outcome
time O
of O
main O
symptoms O
(fever, O
fatigue, O
cough) O
Disappearance O
rate O
of O
single O
symptom O
in O

The O
incidence B-outcome
rate I-outcome
of O
complication O

CRP O
IL-6 O
TNF-alpha O
time O
of O
improvement O
of O
clinical O
symptoms O
(fever, O
cough) O

nan O

T B-outcome
cell O
recovery O
time O
Remission O
time O
of O

Level O
of B-outcome
IL2, I-outcome
IL4, O
IL6, O
IL10, O
TNF-alpha O
and O
IFN-gama O
Routine O
blood O
test O
lymphocyte O
subsets O

Comparison O
of O

nan O

Inflammatory O
markers O

Time B-outcome
to O
Clinical O

nan O

Proportion O
of O
severe O
cases O
Length O

nan O

Remission O
time B-outcome
of O

The O
fading O
and O
obviously I-outcome
improving O
time B-outcome
of I-outcome
clinical O

ICU O
length O
of O
stay I-outcome
Chest O
CT B-outcome
Routine I-outcome

Remission O
time O
of O
fever O

Time O
of B-outcome
improvement I-outcome
of O
clinical O
symptoms O
Remission O

Time O
and O
rate O
of O
coronavirus B-outcome
become I-outcome

Time O
and O
rate O

Chest O
distress O
Fatigue O
Sleep O
quality O

Time O
and I-outcome
rate O

Time O
and O
rate O
of O
coronavirus O
become O
negative O
Clearance O

Lung O
function O
oxygenation O
index B-outcome

Evaluation I-outcome

Blood B-outcome
count I-outcome
liver I-outcome
and O

nan O

nan O

PHQ-9 O
A O
Coping O

nan O

Total O

nan O

Secondary O
symptom O
grading O
quantification O
table O

nan B-outcome

nan I-outcome

Dyspnea I-outcome
evaluation I-outcome

nan B-outcome

nan I-outcome

nan I-outcome

Improving I-outcome

Recurrence B-outcome
rate I-outcome
of I-outcome
COVID-19 I-outcome

WBC O
PBML O

Causal B-outcome
mortality I-outcome
COVID-19 I-outcome
nucleic I-outcome

hepatic O
and O

Differences O
in O
mean O
clinical O

time O
till O
the O
SARS-CoV-2 O
clearance O

Adverse O
events B-outcome

Progression O

Duration O
of O
hospitalization O
Clinical B-outcome
outcome I-outcome

Duration B-outcome
of I-outcome
hospitalization I-outcome
Mortality I-outcome

Duration B-outcome
of O
hospitalization O

nan O

Hospitalization O
duration O
Lung O

Duration O
of O
hospitalization O
Clinical O
outcome O
(cure O
or O
death) O

Requirement O
for B-outcome
mechanical B-outcome
ventilation B-outcome
Radiological I-outcome
changes B-outcome
Serious O
adverse O
events O
All-cause O

Duration B-outcome
of I-outcome
hospitalization I-outcome
Clinical I-outcome

The O
time O
from O

Duration B-outcome
of I-outcome
severe I-outcome

disappearance O
rate O
of O

disappearance B-outcome
rate O
of O
COVID-19 O

1. B-outcome
Proportion I-outcome
of O
subjects O
with O

nan O

virological O
clearance O
overtime O
during O
the B-outcome
study I-outcome
period I-outcome
clinical B-outcome
follow-up B-outcome
(body O

nan O

nan B-outcome

time O

nan O

nan O

Heart O
Failure O
Pulmonary O
Edema O
Allergic O

Intensive O
Care O
Unit O
Admission O

Absolute B-outcome
change O
in O
serum I-outcome
troponin B-outcome
from I-outcome
admission I-outcome
Discharge I-outcome
Rate B-outcome
Intubation B-outcome
Rate B-outcome

change I-outcome

Intensive O
Care O
Unit O

nan O

Requirement O
for O
non-invasive O
or O
mechanical O
ventilation O
Length O
of O
hospital O
stay O
in O
days O
Estimated I-outcome
PaO2/FiO2 O

Decrease O

All O
cause O

Overall O

Response O
of O

Patients O
achieving O

Time O
to O
clinical O
improvement O
Clinical O
status O
Mean O
change B-outcome
in B-outcome
clinical B-outcome
status I-outcome
from B-outcome

Rate O
of O

composite O
of O
invasive O
mechanical O

Hospital-free B-outcome
days I-outcome
at I-outcome
28 I-outcome

Necessity O
of O

Time O
to O

Rate O
of B-outcome
housemate O

all-location, O
all-cause O
mortality O
assessed O
on O
day O
15 O
all-location, O
all-cause O
mortality O
assessed O
on O
day O
29 O

Viral O
load O
Viral O
load O
Mortality O
Adverse O
events O
Positive O
SARS-CoV-2 O
test O
- O
nasal O
swab O

Days B-outcome
of I-outcome
stay O
in O
the O
ICU O

Days O
on I-outcome
invasive O
mechanical O
ventilation O

Change O
in O
Respiratory O
Rate O
Change O
in O
Heart O
Rate O
Change O
in O
Blood O
Pressure O

SAE O
Serious O
ADR O

Hospital O
length O

Lengh O
of O

Time O
to O
improvement O
in O
oxygenation O
Mean O
change O
in O
oxygenation O
Number O
of O

Changes O
of O
CD3 O
Changes O
of O
CD3 O
Changes O
of O
CD3 O
Changes O
of O

Viral O
load O
Change O
in I-outcome
Clinical O
Condition O

Pulmonary O
Function O
Analysis O

nan O

Incidence O

Physical O
statues O
of O
patient O

Primary O
safety O
endpoint: O
major O
adverse O
cardiac O
events O

Ventilator-free O
days O

SARS-CoV-2 O

nan O

Anti-SARS-CoV-2 O
titers B-outcome
Anti-SARS-CoV-2 O
titers O

nan O

C-reactive B-outcome
proteins O
Lymphocyte O

Change B-outcome
from I-outcome
baseline O
Weight O
at O

Number O
of O

Type O
of O
respiratory B-outcome
support O
Duration O

PCR O
levels O
Lactate O
clearance O

Change O
from O
baseline O
to O
Day O
5 O
in O

30-day-survival O
vasopressor O

Status O
on O
an O
ordinal O
scale O
assessed B-outcome
daily O
while O
hospitalized O
and O
on O
days O
15 O
and O
29 O
and O
180. O

time O
to O
extubation O
length O
of B-outcome
intensive I-outcome
care O
unit O

Safety O
evaluation, O
as O
measured O
by O
AEs, O
Adverse B-outcome
Reactions I-outcome
(ARs), Seperator
SAEs, I-outcome
Serious O
ARs I-outcome
(SARs) B-outcome
Clinical B-outcome
status B-outcome
as I-outcome
assessed O

Evaluation O
of O
the O
clinical O
status O
All-cause O
mortality B-outcome
Mechanical B-outcome
ventilation B-outcome
duration O
Sequential O
Organ O

Number O
of O
patients O
with O
severe B-outcome
disease O
as O

All O
cause O
mortality O
Systemic O
inflammation O

Time O
to O
Clinical O
Improvement O
(TTCI), O
Defined O

nan O

Lung O
injury O
score O
Oxygenation O
index O
In-hospital B-outcome
mortality O

ICU O
free O
days O
Hospital O
length O
of B-outcome
stay I-outcome

nan O

need O
of O
admission O
in O
intensive O
care O
unit O
death O
rate O
of O
adverse O
events O

All-cause O

Time O
to I-outcome
SARS-CoV-2 I-outcome

Time O

Efficacy O
of O
PP O
(Prone B-outcome
Positioning) I-outcome

Death O
Clinical O
status O
Mechanical O
venhtilation O
Hospitalization O
Time O
from O
treatment O
initiation O
to O
death O
Time O
to O
Negativization O
COVID O
19 O
Fever O

reduction O
of O
C-reactive O
protein O
or O
CRP O
Reduction O
of O
mechanical O
ventilation O

The O
percentage O
of O

30 O
days O

Respiratory O
rate O
Heart O
rate O
Blood O
pressure O

Occurrence O
and O
duration O

Mortality O
rate O
at O
D30 O
Time O

The O
differences O
in O
oxygen I-outcome
intake O

Number O
of O
death O

Ordinal O
scale O
in O

Phase O
2: O
The O
time O
to O

Absolute O
mortality O
on O
days O

Composite O
outcome:composite O

nan O

Treatment O

WHO O
progression O
scale O

Number O

WHO O
progression O

Categorization O
of O
hospitalization O

All-cause B-outcome
mortality I-outcome
rate I-outcome
(main O
study) O

nan B-outcome

Measure O

Clinical O
cure O
rate B-outcome

30-day O
mortality O

Number O
of O
participants O

Number O
of O

All-cause B-outcome
mortality O
Incidence O

Oxygenation O
Mechanical O
Ventilation O
Hospitalization O

Time O
to O
category O

Time O
of O
clinical O
recovery I-outcome
of B-outcome
fever I-outcome
Time B-outcome
of I-outcome
clinical B-outcome
recovery I-outcome

Duration O
of I-outcome
hospitalization O
Duration O
of O
mechanical I-outcome
ventilation B-outcome
Time O

Cardiac O
arrest O
Transfer O
to O

Clinical O

LDH O
level O

Safety O
of O

The O
proportion O

Time B-outcome
to I-outcome
clinical I-outcome
recovery I-outcome

nan O

Difference O

nan O

Number O
of O
days O
on O
supplemental O

nan O

Rates O
of O
death O
during O

Phase O
2: O
Change O
in O
the O
8-point O

Change O
in O

Time O
from O
randomization O

In-hospital O
mortality O
All-cause O
mortality O

Montgomery O
√Ösberg O

Incidence O
of O
GI O
adverse O
events O
Cardiac O
Toxicity O

The O
number O
of O

Rate O
of B-outcome
mortality O
within O
28-days O
Size O
of O
lesion O
area O

Lung O
lesion O
Immune B-outcome
function I-outcome
Time O
of O
SARS-CoV-2 O
clearance O
Blood O
test O

Days O
of O
respirator O

nan O

Impact O
of O
300ml O
convP O

Inpatient O
hospitalizations O
required O

nan O

Assessment O
of O

Number O
of O
days O

Symptom B-outcome
questionnaire I-outcome
Fever I-outcome
assessment I-outcome
Vital O
Signs O
- O
Body O
Temperature O
Discharge O
Recovery O

Adverse O
events O

nan O

Survival O

clinical B-outcome
deterioration O

Number O

The O

Days O

Duration O

Mortality O
SpO2 O

Illness B-outcome
severity I-outcome
Number I-outcome
of O
patients O
with O
clinical O
improvement O

Decrease O
renal O
injury O

Safety O
& O
Tolerability: O
incidence O

Length O
of O
time O
participant O
spends O
in O
the O

Time O
to O
reach O
an O
afebrile O

Undetectable O
COVID O
PCR O
at O
day O

Length O
of O
time O
tolerating O
prone O

Time O
to O

World O
Health O
Organisation(WHO) O
progression O
scale O
‚â§5 O

Oxygen O
requirement O
of O
the O
patient B-outcome
Oxygen O

Death O
Mechanical O
ventilation O
Intensive O
care B-outcome
unit O

Overall O
survival O
Overall O
survival O
Cumulative B-outcome
incidence O

Early O
improvement: O
OMS O
progression O
scale O
<= O

Evolution O

Saturation B-outcome
of I-outcome
Oxygen I-outcome
in I-outcome
the O
blood O

nan B-outcome

Clinic I-outcome
at I-outcome
hospitalization I-outcome

Increase O
in O
oxygen B-outcome
saturation O
PaO2/FiO2 O
>300mmHg O
increase O
Reduction O
of O
IL-6 O

Incidence O
of O

nan O

Time O
to O
clinical O

Proportion O
of O
patients O
who O
avoided O

Proportion O
(%) O
of O

Clinical O
outcome O
Hospital O
stay O

Myocardial O
infarction O
Congestive O
cardiac B-outcome
failure I-outcome

Mortality O
rates O
Number O
of O
defined O
daily O
dose O

OMS B-outcome
progression I-outcome
scale I-outcome
‚â§5 I-outcome

Comparison O
of O
change O
of O
baseline B-outcome
total I-outcome
sequential O
organ O
failure O
assessment O
(SOFA) O
score O
in O
enrolled O
subjects O
towards O
historical O
comparators O
Comparison O
of O
change O
of O
lung O
involvement O
measurements O
in O
enrolled O
subjects O
towards O
historical O

Clinical O
improvement O
by O
WHO B-outcome

nan O

All-cause O
mortality O
(intention B-outcome
to I-outcome
treat) O
Ventilator-free B-outcome
days I-outcome
(VFD) O
All-cause B-outcome
mortality I-outcome
with O
per O
protocol O
analysis O

Arterial O
thrombosis O

Duration O
of O

nan O

Fever O

Changes O

Proportion O

90 O

nan O

Clinical O

Number O
of O
death O
of O

Change O
in O
estimated O
PaO2/FiO2 O
Number O

Ventilator-free O
days O

Mortality O
rate O
Number O

Time B-outcome
to I-outcome
improvement I-outcome
of I-outcome
2 O

Overall B-outcome
survival I-outcome
Reduction I-outcome
in I-outcome
proportion O
of O
patients O
who O
require O
ventilation O
Reduction O
in O
length O
of O
Critical O
Care O
stay O
Reduction O
in O

Proportion O
of O

All-cause-mortality O
Acute-inflammation-free O

nan O

proportion O
of O
"persistent O
responders" O

WHO O
progression O

Time O
fever O
resolution B-outcome

1st O
secondary O

All-Cause O
Death O
Length O
of O

Comfort O
with O
the B-outcome
interfaces I-outcome

Changes O
in O

Changes O
in O
compound O

Symptom O
Resolution: O
Fever O
Symptom O

nan O

Hospital O
re-admission O
Emergency O
Department O
visit O
Urgent O
Care O

ICU O
mortality O

Immune O
biomarkers, O

Improving O
of O
PSQI, B-outcome
Improving O
of O

SOFA, O
Serum O

Rate O
of O
progression O
to O
severe O

Self-Rating O
Anxiety I-outcome
Scale O

novel O
coronavirus O
nucleic B-outcome
acid I-outcome
clearance O
rate, O

Clinical B-outcome
Severity I-outcome
Oxygenation: O
Mechanical O

1 O
- O
Percent B-outcome
of O
patients O
alive O

Receipt O
of O

Duration B-outcome
of O

nan B-outcome

nan O

DLco%, I-outcome
6MWT, O

Pharmacokinetics: O
AUCinf O
ÔºåAUC0-t O
ÔºåAUC0-tauÔºåCmaxÔºåTmaxÔºåt1/2ÔºåCLÔºåVzÔºåMRTinfÔºåRac(AUC)ÔºåRac(Cmax) O

nan O

- B-outcome
to I-outcome
study O

Severe O
respiratory O
failure O

‚Ä¢ O
Change O
in O
NEWS O

1. O
Log O
transformed O

1. O
ingresso O
in O
Terapia O

- O

- O

1) O

Level I-outcome
of I-outcome
frailty I-outcome

Side B-outcome
effects I-outcome

-Time I-outcome
since I-outcome

‚Ä¢ B-outcome
Comparison I-outcome
of I-outcome
the I-outcome

Achievement B-outcome
of I-outcome
free O

Number B-outcome
of I-outcome
days O

WHO O
7-point O
outcome O
scale B-outcome
(clinician I-outcome
assessed): I-outcome
Not O
hospitalized, B-outcome
no I-outcome
limitations I-outcome

Intubation O
rate O
Time B-outcome
to I-outcome
intubation I-outcome
Time I-outcome
to I-outcome
death I-outcome
(mortality), I-outcome
obtained I-outcome

Duration O
of O
hospital B-outcome
stay I-outcome
(hours) I-outcome
Time I-outcome
to O
first B-outcome
receiving I-outcome
ventilation I-outcome

Recovery O
time, O
Virus B-outcome
nucleic I-outcome
acid I-outcome
negative O
time B-outcome
and I-outcome
rate, I-outcome
The I-outcome

novel B-outcome
coronavirus O
nucleic O
acid B-outcome
detection I-outcome

Severity I-outcome

28-day O
mortality O
Need B-outcome
for I-outcome
ICU I-outcome
admission O
Length B-outcome
of I-outcome
ICU I-outcome

Time O
to O

toxicity O

Ventilator-free O

mortality O
Duration O
of O
mechanical O
ventilation O
Duration O
of O
oxygen O

The O
major O
secondary O

Adverse O
reactions O

- O
Sociodemographic O

all-cause B-outcome
mortality I-outcome
at I-outcome
D28 O

- B-outcome
To I-outcome
asses I-outcome
in O

‚Ä¢ B-outcome
Number I-outcome
of O

Number O
of O

Time O
to O
clinical O

The O
cycle O
threshold O
for O
SARS-CoV-2 B-outcome
PCR, O

-time O
to O

1. O
Phase O
2 O
and O

Secondary O
end O

nan B-outcome

1. O

overall B-outcome
survival O
through O

nan O

time O
to O
recovery O

1) O
the O
rate O
of O
positive-to-negative O
conversion O
of O

latency O
to O
pyrexia O
relief O

nan O

nan O

nan O

nan O

Exercise O

rate O
of O
hospital O

improvement O
of O
clinical O
symptoms O
laboratory O

total B-outcome
lymphocyte O
count B-outcome
subpopulation O

Rate O
of O
mortality O
within B-outcome
28-days I-outcome
Sequential I-outcome
organ I-outcome
failure I-outcome
assessment O
Side O
effects O
in O

P/F O
ratio O
over O
time O
Sequential B-outcome
organ I-outcome
failure I-outcome
assessment I-outcome
score(SOFA O
score) O
over O
time O
Pulmonary O
Severity O
Index O
(PSI) O
Image O
examination O
of O
chest O
over O
time O

Survival O
at O
28 B-outcome
days I-outcome
Survival O
at O
90 O
days O
SARS-free O
days O
at O
28 O
days O
SARS O
-free O
days O
at O
90 O
days O
Renal O
Replacement O
Therapy O
Liver O
Failure O
Mechanical O
Support O
of O
Circulation O

nan B-outcome

Self-rating I-outcome
depression I-outcome
scale I-outcome

